{"id":"W2789846395","doi":"10.1056/nejme1800041","title":"Edoxaban for the Treatment of Venous Thromboembolism in Patients with Cancer","year":2018,"lang":"en","type":"letter","venue":"New England Journal of Medicine","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Warfarin; Venous thromboembolism; Edoxaban; Heparin; Cancer; Randomized controlled trial; Low molecular weight heparin; Anticoagulant; Anticoagulant therapy; Major bleeding; Internal medicine; Surgery; Thrombosis; Rivaroxaban","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006563066,0.0003320093,0.0007025547,0.0005088571,0.001031756,0.0008715604,0.0005127943,0.006545789,0.004313574],"category_scores_gemma":[0.006706788,0.0001371125,0.000525239,0.0005798369,0.0008996829,0.001099739,0.0004027364,0.006399602,0.003075102],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001415023,"about_ca_system_score_gemma":0.00104197,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008085138,"about_ca_topic_score_gemma":0.001629819,"domain_scores_codex":[0.9993253,0.0002664376,0.00008453496,0.00004948703,0.0001986184,0.0000756845],"domain_scores_gemma":[0.9989854,0.000581282,0.0001462934,0.00003265146,0.000121464,0.0001329713],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0004817033,0.0003313612,0.01101755,0.0006893296,0.00007274636,0.1044656,0.000588275,0.0003763468,0.001753005,0.009910682,0.6942785,0.176035],"study_design_scores_gemma":[0.0007303096,0.0008421864,0.01207409,0.003468927,0.0001171581,0.283242,0.0005650207,0.001651193,0.0009206806,0.02457083,0.6717443,0.000073299],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"editorial","genre_scores_codex":[0.01284776,0.04938494,0.0008730595,0.888418,0.01499775,0.00008831517,0.00007810185,0.0001167527,0.03319538],"genre_scores_gemma":[0.1335566,0.05878616,0.001825752,0.6952302,0.09577291,0.0001399184,0.000171063,0.00005307009,0.01446429],"genre_candidate":"editorial","genre_consensus":null,"teacher_disagreement_score":0.006545789,"threshold_uncertainty_score":0.0144304,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02120724867016575,"score_gpt":0.2848213043194892,"score_spread":0.2636140556493234,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}